Lineage Cell Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Tax Assets, Operating Loss Carryforwards of $70.64 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $70.64M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $68.18M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $63.46M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $58.82M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $70.64M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $68.18M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $63.46M 10-K · filed 2025-03-10 | |
| 2022-12-31 | $58.82M 10-K · filed 2024-03-07 | |
| 2021-12-31 | $68.77M 10-K · filed 2023-03-09 | |
| 2020-12-31 | $63.94M 10-K · filed 2022-03-10 | |
| 2019-12-31 | $62.06M 10-K · filed 2021-03-11 | |
| 2018-12-31 | $37.76M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $55.61M 10-K · filed 2019-03-14 | $55.61K 10-K · filed 2018-03-15 |
| 2016-12-31 | $78.12K 10-K · filed 2018-03-15 | $78.12M 10-K · filed 2017-03-16 |
| 2015-12-31 | $78.27M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $58.69M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $5.17M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $2.86M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $1.35M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $46.71M 10-K · filed 2015-03-11 | |
| 2012-12-31 | $36.11M 10-K · filed 2014-03-17 | |
| 2011-12-31 | $32.58M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |